• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Dexcom Appoints Jon Coleman as Chief Commercial Officer

    3/25/25 4:05:00 PM ET
    $DXCM
    $MASI
    $PFE
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $DXCM alert in real time by email

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience.

    Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolidation of its worldwide hospital sales, OEM, alternate care sales, and clinical teams along with the customer service and hospital conversion teams. Mr. Coleman also held significant roles at Pfizer's (NYSE:PFE) Consumer Healthcare business, leading as vice president and general manager of Canada and the Caribbean region after several years of regional leadership in Asia and Latin America. Across his various roles at these organizations, Mr. Coleman established a track record of scaling operations, developing innovative products, entering new markets, and delivering strong growth performance.

    "Jon has demonstrated the ability to lead organizations through the complexities of global healthcare with consistently strong performance across a variety of sectors and channels," said Kevin Sayer, chairman, president and chief executive officer at Dexcom. "This broad experience across market segments and regions provides a great fit as we look to capitalize on Dexcom's incredible growth opportunity."

    "Dexcom's commitment to drive innovation in glucose biosensing and its unique long-term growth opportunity make the chief commercial officer role an incredible opportunity," said Mr. Coleman. "I am excited to lead this great team at a key point in the company's history and execute on the company's ambitious vision to empower greater health around the world."

    About Jon Coleman

    Prior to his role as president – Worldwide OEM & Global Health at Masimo, Mr. Coleman held several roles of increasing responsibility at Masimo including president – Worldwide Sales, Professional Services, Medical Affairs, and OEM and president – International. Before joining Masimo, he was general manager – Americas region for Targus Group International, Inc. Before that, Mr. Coleman spent more than a decade in leadership of the Consumer Healthcare business at Pfizer, revitalizing growth as vice president and general manager – Canada and Caribbean region and driving double-digit growth as region director – Asia. Before joining Pfizer, Mr. Coleman began his career with roles at the Procter & Gamble Company and Bain & Company.

    Mr. Coleman earned an M.B.A. from Harvard Business School and a Bachelor of Arts degree in International Relations from Brigham Young University.

    About DexCom, Inc.

    Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

    Dexcom. Discover what you're made of. For more information, visit www.dexcom.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250325396614/en/

    Media Contact

    James McIntosh

    619-884-2118

    [email protected]



    Investor Contact

    Sean Christensen

    858-203-6657

    [email protected]

    Get the next $DXCM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $DXCM
    $MASI
    $PFE

    CompanyDatePrice TargetRatingAnalyst
    DexCom Inc.
    $DXCM
    6/16/2025$102.00Buy
    Truist
    DexCom Inc.
    $DXCM
    5/30/2025$104.00Buy
    Goldman
    Pfizer Inc.
    $PFE
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    DexCom Inc.
    $DXCM
    4/10/2025$85.00Outperform
    Mizuho
    DexCom Inc.
    $DXCM
    2/3/2025$85.00 → $115.00Neutral → Buy
    Redburn Atlantic
    DexCom Inc.
    $DXCM
    1/16/2025$86.00 → $104.00Neutral → Outperform
    Robert W. Baird
    Masimo Corporation
    $MASI
    12/27/2024$170.00 → $194.00Outperform
    Raymond James
    Pfizer Inc.
    $PFE
    12/10/2024$29.00Neutral
    BofA Securities
    More analyst ratings

    $DXCM
    $MASI
    $PFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

      4 - PFIZER INC (0000078003) (Issuer)

      2/14/25 5:16:36 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Gottlieb Scott bought $28,240 worth of shares (1,000 units at $28.24), increasing direct ownership by 11% to 10,000 units (SEC Form 4)

      4 - PFIZER INC (0000078003) (Issuer)

      10/31/24 4:06:54 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gottlieb Scott bought $79,401 worth of shares (3,000 units at $26.47), increasing direct ownership by 50% to 9,000 units (SEC Form 4)

      4 - PFIZER INC (0000078003) (Issuer)

      12/19/23 9:31:01 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DXCM
    $MASI
    $PFE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 25, 2024 - FDA Roundup: October 25, 2024

      For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

      10/25/24 2:48:21 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for HYMPAVZI issued to PFIZER INC

      Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

      10/15/24 2:57:27 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

      For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

      10/11/24 2:12:15 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DXCM
    $MASI
    $PFE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

      XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical recurrence (BCR) Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as nonmetastatic castration-sensitive prostate cancer or nmCSPC) with biochemical recurrence (B

      7/10/25 6:45:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Masimo Joins Innovators' Network at American Heart Association Center for Health Technology & Innovation

      American Heart Association Consortium Advances Development of Evidence-based Health Tech Solutions Masimo (NASDAQ:MASI), a global medical technology company that develops and manufactures innovative noninvasive monitoring solutions, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708674775/en/Masimo is a member of the American Heart Association's Innovators' Network The Innovators' N

      7/8/25 8:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time.

      DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Management will hold a conference call to review the company's second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the

      7/1/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    $MASI
    $PFE
    Leadership Updates

    Live Leadership Updates

    See more
    • Masimo Joins Innovators' Network at American Heart Association Center for Health Technology & Innovation

      American Heart Association Consortium Advances Development of Evidence-based Health Tech Solutions Masimo (NASDAQ:MASI), a global medical technology company that develops and manufactures innovative noninvasive monitoring solutions, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708674775/en/Masimo is a member of the American Heart Association's Innovators' Network The Innovators' N

      7/8/25 8:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Dexcom Launches First Nationwide Search for College Athletes With Diabetes to Join Season Four of Dexcom U

      Dexcom's first-of-its-kind NIL program is accepting nominations for passionate and inspiring college athletes with diabetes for its 2025 roster now through May 23. Selected athletes will be invited to the Dexcom U Signing Day Camp this summer, hosted by Dexcom Warrior and Baltimore Ravens tight end Mark Andrews. DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, Image and Likeness program exclusively for college athletes with diabetes – for an expanded fourth season, including the first-ever nationwide open call for passionate and inspiring college athletes to join its roster. This press release features

      4/22/25 8:00:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom Appoints Jon Coleman as Chief Commercial Officer

      DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

      3/25/25 4:05:00 PM ET
      $DXCM
      $MASI
      $PFE
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Biotechnology: Pharmaceutical Preparations

    $DXCM
    $MASI
    $PFE
    Financials

    Live finance-specific insights

    See more
    • Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time.

      DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Management will hold a conference call to review the company's second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the

      7/1/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Pfizer Declares Third-Quarter 2025 Dividend

      Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company's common stock, payable September 2, 2025, to holders of the Common Stock of record at the close of business on July 25, 2025. The third-quarter 2025 cash dividend will be the 347th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery,

      6/25/25 5:30:00 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts

      Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, August 5, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Second Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also listen to the confere

      6/25/25 10:00:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DXCM
    $MASI
    $PFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Masimo Corporation

      SC 13D/A - MASIMO CORP (0000937556) (Subject)

      9/25/24 4:01:23 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Masimo Corporation

      SC 13D/A - MASIMO CORP (0000937556) (Subject)

      8/30/24 4:56:53 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Masimo Corporation

      SC 13D/A - MASIMO CORP (0000937556) (Subject)

      7/17/24 5:29:36 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $DXCM
    $MASI
    $PFE
    SEC Filings

    See more
    • SEC Form 11-K filed by Masimo Corporation

      11-K - MASIMO CORP (0000937556) (Filer)

      6/25/25 6:45:01 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 11-K filed by Pfizer Inc.

      11-K - PFIZER INC (0000078003) (Filer)

      6/16/25 4:12:32 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Pfizer Inc.

      11-K - PFIZER INC (0000078003) (Filer)

      6/16/25 4:07:31 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DXCM
    $MASI
    $PFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Gala Renee D was granted 1,161 shares, increasing direct ownership by 20% to 6,881 units (SEC Form 4)

      4/A - DEXCOM INC (0001093557) (Issuer)

      7/7/25 4:15:09 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Taraporevala Cyrus

      4 - PFIZER INC (0000078003) (Issuer)

      7/2/25 4:39:02 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Smith James C

      4 - PFIZER INC (0000078003) (Issuer)

      7/2/25 4:38:59 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DXCM
    $MASI
    $PFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Dexcom with a new price target

      Truist initiated coverage of Dexcom with a rating of Buy and set a new price target of $102.00

      6/16/25 7:46:45 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Goldman initiated coverage on Dexcom with a new price target

      Goldman initiated coverage of Dexcom with a rating of Buy and set a new price target of $104.00

      5/30/25 8:41:14 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Cantor Fitzgerald initiated coverage on Pfizer with a new price target

      Cantor Fitzgerald initiated coverage of Pfizer with a rating of Neutral and set a new price target of $24.00

      4/22/25 8:03:45 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care